Neonatal Phase 1 Valacyclovir Study (NCT05468619) | Clinical Trial Compass
CompletedPhase 1
Neonatal Phase 1 Valacyclovir Study
United States17 participantsStarted 2023-08-07
Plain-language summary
A Phase 1 study that will determine the valacyclovir dose that results in a systemic acyclovir exposure comparable to 10 mg/kg of parenterally administered acyclovir, which is an AUC0-12 of 24,000 ngxhr/mL to 48,000 ngxhr/mL. Neonates at risk of acquiring neonatal HSV will be enrolled in one of 2 cohorts. Cohort 1 will be comprised of eight subjects who will receive an initial dose of 10ml/kg of oral valacyclovir. Samples for PK assessments will be obtained to assess the exposure concentration. If the safety profile and the drug exposure concentrations in Cohort 1 are acceptable, eight new subjects will be enrolled in Cohort 2. The dose that these subjects will receive will be predicated upon the pharmacokinetic data from Cohort 1.
Who can participate
Age range1 Day – 2 Days
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Signed informed consent from parent(s) or legal guardian(s)
✓. Maternal history of genital HSV infection
✓. Maternal receipt of oral acyclovir, valacyclovir, or famciclovir suppressive therapy for \>/= 7 days prior to delivery
✓. Gestational age \>/= 38 weeks at birth
✓. \</= 2 days of age at study enrollment\*
✓. Weight at study enrollment \>/= 2,000 grams
Exclusion criteria
✕. Evidence of neonatal HSV infection
✕. Evidence of sepsis
✕. Known renal anomalies or dysfunction
✕. Maternal genital lesions suspicious for HSV at the time of delivery
✕. Infants known to be born to women who are HIV positive (but HIV testing is not required for study entry)
What they're measuring
1
Neonatal plasma acyclovir mean AUC12 concentrations
Timeframe: Days 1 - 5
Trial details
NCT IDNCT05468619
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)